TCRT - Alaunos Therapeutics, Inc. Stock Price, Fair Value and News

$2.04-0.02 (-0.97%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

TCRT Price Action

Last 7 days

-4.0%

Last 30 days

-44.9%

Last 90 days

-42.3%

Trailing 12 Months

-85.5%

TCRT RSI Chart

TCRT Valuation

Market Cap

3.3M

Price/Earnings (Trailing)

-0.17

Price/Sales (Trailing)

730.17

Price/Free Cashflow

-0.19

TCRT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

TCRT Fundamentals

TCRT Revenue

Revenue (TTM)

5.0K

TCRT Earnings

Earnings (TTM)

-19.1M

Earnings Growth (Yr)

87.13%

Earnings Growth (Qtr)

32.88%

TCRT Profitability

Return on Equity

-507.29%

Return on Assets

-408.94%

Free Cashflow Yield

-526.23%

TCRT Investor Care

Buy Backs (1Y)

0.18%

Diluted EPS (TTM)

-12.66

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	0	2.2M	1.1M	5.0K
2022	0	0	3.3M	3.3M
2021	0	0	272.0K	398.0K
2018	4.8M	3.3M	1.7M	146.0K
2017	6.5M	6.4M	6.4M	6.4M
2016	6.0M	7.5M	7.2M	6.9M
2015	1.4M	1.5M	2.8M	4.3M
2014	800.0K	800.0K	1.2M	1.4M
2013	800.0K	800.0K	800.0K	800.0K
2012	800.0K	800.0K	800.0K	800.0K
2011	0	0	0	667.0K
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Alaunos Therapeutics, Inc.

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor engine. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. was founded in 2003 and is headquartered in Houston, Texas.

CEO	Mr. Kevin S. Boyle Sr.
WEBSITE	alaunos.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	34

Alaunos Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Alaunos Therapeutics, Inc.? What does TCRT stand for in stocks?

TCRT is the stock ticker symbol of Alaunos Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Alaunos Therapeutics, Inc. (TCRT)?

As of Mon Oct 28 2024, market cap of Alaunos Therapeutics, Inc. is 3.3 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TCRT stock?

You can check TCRT's fair value in chart for subscribers.

Is Alaunos Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether TCRT is over valued or under valued. Whether Alaunos Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Alaunos Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TCRT.

What is Alaunos Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Oct 28 2024, TCRT's PE ratio (Price to Earnings) is -0.17 and Price to Sales (PS) ratio is 730.17. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TCRT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Alaunos Therapeutics, Inc.'s stock?

In the past 10 years, Alaunos Therapeutics, Inc. has provided -0.416 (multiply by 100 for percentage) rate of return.